Alphatec Stock Forecast, Price & News

+0.18 (+1.27 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.18 million shs
Average Volume716,490 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

Alphatec logo

About Alphatec

Alphatec Holdings, Inc. engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. The company was founded on March 4, 2005 and is headquartered in Carlsbad, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.43 out of 5 stars

Medical Sector

151st out of 1,349 stocks

Surgical & Medical Instruments Industry

16th out of 123 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

Is Alphatec a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alphatec stock.
View analyst ratings for Alphatec
or view top-rated stocks.

What stocks does MarketBeat like better than Alphatec?

Wall Street analysts have given Alphatec a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alphatec wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alphatec?

Alphatec saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 5,140,000 shares, an increase of 116.9% from the July 29th total of 2,370,000 shares. Based on an average trading volume of 729,100 shares, the short-interest ratio is currently 7.0 days. Approximately 8.4% of the shares of the company are sold short.
View Alphatec's Short Interest

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Alphatec

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) announced its earnings results on Monday, August, 2nd. The medical technology company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.20. The medical technology company had revenue of $62.25 million for the quarter, compared to the consensus estimate of $51.20 million. Alphatec had a negative trailing twelve-month return on equity of 86.64% and a negative net margin of 54.09%.
View Alphatec's earnings history

How has Alphatec's stock price been impacted by COVID-19 (Coronavirus)?

Alphatec's stock was trading at $4.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATEC shares have increased by 224.3% and is now trading at $14.30.
View which stocks have been most impacted by COVID-19

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its FY 2021 earnings guidance on Tuesday, August, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $238 million-$238 million, compared to the consensus revenue estimate of $187.40 million.

What price target have analysts set for ATEC?

7 brokers have issued 12-month price objectives for Alphatec's stock. Their forecasts range from $13.00 to $24.00. On average, they expect Alphatec's stock price to reach $19.79 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price.
View analysts' price targets for Alphatec
or view top-rated stocks among Wall Street analysts.

Who are Alphatec's key executives?

Alphatec's management team includes the following people:
  • Patrick S. Miles, Chairman, President, CEO & COO
  • J. Todd Koning, Chief Financial Officer & Executive Vice President
  • Luiz Pimenta, Chief Medical Officer
  • Scott Lish, Senior Vice President-Research & Development (LinkedIn Profile)
  • Michael T. Dendinger, Vice President-Operations

What is Pat Miles' approval rating as Alphatec's CEO?

7 employees have rated Alphatec CEO Pat Miles on Pat Miles has an approval rating of 72% among Alphatec's employees.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.96%), Vanguard Group Inc. (3.16%), State Street Corp (1.89%), First Light Asset Management LLC (1.76%), Next Century Growth Investors LLC (1.56%) and Geode Capital Management LLC (1.11%). Company insiders that own Alphatec stock include Craig E Hunsaker, David R Pelizzon, David Sponsel, James L L Tullis, James L L Tullis, Jeffrey G Black, Jeffrey P Rydin, Jennifer N Pritzker, Jennifer N Pritzker and Scott Lish.
View institutional ownership trends for Alphatec

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Point72 Asset Management L.P., Next Century Growth Investors LLC, Federated Hermes Inc., Russell Investments Group Ltd., Marshall Wace LLP, Marshall Wace LLP, and Parametric Portfolio Associates LLC. Company insiders that have sold Alphatec company stock in the last year include Craig E Hunsaker, David Sponsel, James L L Tullis, Jeffrey G Black, and Scott Lish.
View insider buying and selling activity for Alphatec
or view top insider-selling stocks.

Which major investors are buying Alphatec stock?

ATEC stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, BlackRock Inc., Vanguard Group Inc., State Street Corp, Armistice Capital LLC, First Trust Advisors LP, Morgan Stanley, and Morgan Stanley. Company insiders that have bought Alphatec stock in the last two years include David R Pelizzon, David Sponsel, and Jennifer N Pritzker.
View insider buying and selling activity for Alphatec
or or view top insider-buying stocks.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $14.30.

How much money does Alphatec make?

Alphatec has a market capitalization of $1.43 billion and generates $144.86 million in revenue each year. The medical technology company earns $-78,990,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Alphatec have?

Alphatec employs 296 workers across the globe.

When was Alphatec founded?

Alphatec was founded in 1990.

What is Alphatec's official website?

The official website for Alphatec is

Where are Alphatec's headquarters?

Alphatec is headquartered at 5818 EL CAMINO REAL, CARLSBAD CA, 92008.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at (760) 431-9286 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.